These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 36980786)

  • 1. Recent Advances in the Systemic Treatment of Localized Gastroesophageal Cancer.
    Puhr HC; Reiter TJ; Preusser M; Prager GW; Ilhan-Mutlu A
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors in resectable gastroesophageal cancers - a review.
    Mukherjee S; Parmar K; Smyth E
    Ther Adv Med Oncol; 2022; 14():17588359221139625. PubMed ID: 36479471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perioperative immune checkpoint inhibitor therapy for gastric and gastroesophageal junction cancers: a review of current approaches and future perspectives.
    Takahari D; Nakayama I
    Int J Clin Oncol; 2023 Nov; 28(11):1431-1441. PubMed ID: 37500970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Evolving Landscape of Neoadjuvant Immunotherapy in Gastroesophageal Cancer.
    Dennehy C; Khan AF; Zaidi AH; Lam VK
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant and adjuvant approaches in gastroesophageal cancers.
    Scheck MK; Masetti M; Lorenzen S
    Curr Opin Oncol; 2023 Jul; 35(4):318-325. PubMed ID: 37222198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Immunotherapy in Gastroesophageal Cancers-Advances, Challenges and Future Strategies.
    Lynch E; Duffy AG; Kelly RJ
    Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers.
    Karim F; Amin A; Liu M; Vishnuvardhan N; Amin S; Shabbir R; Swed B; Khan U
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy.
    Smyth EC; Gambardella V; Cervantes A; Fleitas T
    Ann Oncol; 2021 May; 32(5):590-599. PubMed ID: 33609722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant and adjuvant therapy in esophageal cancer.
    Weiss JA; Jain S
    J Gastrointest Oncol; 2023 Aug; 14(4):1927-1932. PubMed ID: 37720447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Esophageal, gastric cancer and immunotherapy: small steps in the right direction?
    Zayac A; Almhanna K
    Transl Gastroenterol Hepatol; 2020; 5():9. PubMed ID: 32190777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of immune checkpoint inhibitors for resectable gastric/gastroesophageal cancer.
    Lin F; Chen Y; Huang B; Ruan S; Lin J; Chen Z; Huang C; Zhao B
    Front Pharmacol; 2024; 15():1391562. PubMed ID: 38783944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
    Kelly RJ; Ajani JA; Kuzdzal J; Zander T; Van Cutsem E; Piessen G; Mendez G; Feliciano J; Motoyama S; Lièvre A; Uronis H; Elimova E; Grootscholten C; Geboes K; Zafar S; Snow S; Ko AH; Feeney K; Schenker M; Kocon P; Zhang J; Zhu L; Lei M; Singh P; Kondo K; Cleary JM; Moehler M;
    N Engl J Med; 2021 Apr; 384(13):1191-1203. PubMed ID: 33789008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China.
    Shu Y; Ding Y; Zhang Q
    Front Oncol; 2022; 12():851522. PubMed ID: 35515123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative Systemic Therapy for Resectable Non-Small Cell Lung Cancer.
    Muthusamy B; Patil PD; Pennell NA
    J Natl Compr Canc Netw; 2022 Aug; 20(8):953-961. PubMed ID: 35948038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma.
    Rogers JE; Yamashita K; Sewastjanow-Silva M; Rosa Vicentini E; Waters R; Ajani JA
    Expert Rev Anticancer Ther; 2023 Jun; 23(6):565-571. PubMed ID: 37122102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Perioperative treatment for resectable esogastric adenocarcinoma].
    Dabout V; de la Fouchardière C; Voron T; André T; Huguet F; Cohen R
    Bull Cancer; 2023 May; 110(5):521-532. PubMed ID: 35965103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
    Moehler M; Högner A; Wagner AD; Obermannova R; Alsina M; Thuss-Patience P; van Laarhoven H; Smyth E
    Eur J Cancer; 2022 Nov; 176():13-29. PubMed ID: 36183651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives.
    Zhang Z; Xie T; Zhang X; Qi C; Shen L; Peng Z
    Chin J Cancer Res; 2020 Jun; 32(3):287-302. PubMed ID: 32694895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial.
    Lin Y; Liang HW; Liu Y; Pan XB
    Front Immunol; 2023; 14():1264912. PubMed ID: 37860010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Advances in the Treatment of Gastroesophageal Cancers.
    Li JJ; Rogers JE; Yamashita K; Waters RE; Blum Murphy M; Ajani JA
    Biomolecules; 2023 May; 13(5):. PubMed ID: 37238666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.